Cementless unicompartmental knee replacement allows early return to normal activity

Background: Physical activity and regular participation in recreational sports gain importance in patients’ lifestyle after knee arthroplasty. Cementless unicompartimental Knee replacement with the Oxford System has been introduced into clinical routine. Currently there is no data reporting on the physical activity, return to sports rate and quality of live after medial cementless Oxford Unicompartimental Knee Replacement (OUKR). Methods: This retrospective cohort study reports on the functional outcome of the first 27 consecutive patients (30 knees) that were consecutively treated with a cementless medial OUKR between 2007 and 2009 in our hospital. Physical activity and quality of life were measured using the Tegner-Score, the UCLA-Activity Score, the Schulthess Clinical Activity Questionnaire and the SF-36 Score. The patients’ satisfaction with the outcome was measured using a visual analogue scale. Results: Mean age at surgery was 62.5 years. Patients showed a rapid recovery with 17 out of 27 patients returning to sports within 3 months, 24 within 6 months after surgery. The Return-to-activity-rate was 100%. 10 out of 27 patients showed a high activity level (UCLA ≥7 points) with a mean postoperative UCLA-Score of 6.1 points. Conclusions: Patients recover rapidly after cementless OUKR with a return to sports rate of 100% and patients are able to participate in high impact sports disciplines

Subgroups in the treatment of nasal polyposis with dupilumab A retrospective study

Dupilumab has been shown to be safe and effective in treating chronic rhinosinusitis with polyposis (CRSwNP). There is to this date no published data whether subgroups like patients with aspirin exacerbated respiratory disease (AERD), increased histologic eosinophilia or elevated blood eosinophil or IgE-levels benefit greater from dupilumab therapy. Moreover, there is no data comparing the efficacy of functional endoscopic sinus surgery (FESS) with dupilumab therapy. We conducted a retrospective chart review of all patients that were treated at a tertiary referral center for CRswNP with dupilumab. We also contacted the patients with a questionnaire to evaluate the efficacy of previous surgeries and dupilumab therapy by visual analogue scale (VAS) and the glasgow benefit inventory (GBI) as well as report on side effects. Overall, 75 patients were included in the study at hand that reported back 138 times. While dupilumab treatment was efficient, we found no systematic evidence of greater efficacy of dupilumab in patients with AERD, histologic eosinophilia or increased blood eosinophil or IgE-levels. All patients showed a considerable decrease in subjective burden of disease, objective smell tests and endoscopic findings. From the patients point of view, dupilumab therapy showed greater efficacy both in the VAS and the GBI overall and all subcategories but social support. Dupilumab is efficient in treating CRSwNP;this effect is independent from disease characteristics like AERD, histologic eosinophilia, serum IgE-levels or eosinophil counts. There seems to be a group of patients that benefit greater from dupilumab therapy compared to FESS

Radiolucent lines in the cementless group in the course of time.

<p>Radiolucent lines in the cementless group in the course of time.</p

Zones affected by RL 3 months after surgery, cementless.

<p>Zones affected by RL 3 months after surgery, cementless.</p

Matching-criteria for the cemented and cementless patient group.

<p>Matching-criteria for the cemented and cementless patient group.</p

Zones affected by RL 5 years after surgery, cementless.

<p>Zones affected by RL 5 years after surgery, cementless.</p

Revision and reoperation in patients with and without RL in the cemented group five years after surgery. Cross tabulation.

<p>Revision and reoperation in patients with and without RL in the cemented group five years after surgery. Cross tabulation.</p

Scores of patients with and without RL in the cementless group five years after implantation.

<p>Scores of patients with and without RL in the cementless group five years after implantation.</p